Safety and Effectiveness of Excimer Laser Ablation Combined With Drug-Coated Balloon for Atherosclerotic Obliterans in the Lower Extremity

Restricted accessResearch articleFirst published online October, 2023

Safety and Effectiveness of Excimer Laser Ablation Combined With Drug-Coated Balloon for Atherosclerotic Obliterans in the Lower Extremity

, , [...], and

Volume 30, Issue 5https://doi.org/10.1177/15266028221092979

Abstract

Purpose:

To evaluate the safety and effectiveness of excimer laser ablation (ELA) combined with drug-coated balloon (DCB) for atherosclerotic obliterans (ASO) of the lower extremities.

Materials and Methods:

From June 2019 to December 2020, all eligible patients were enrolled. Demographics, characteristics of lesions, complications, and follow-up information were collected and analyzed. The primary endpoint was major amputation-free survival (MAFS). Secondary endpoints included technical success, primary patency, bailout stent, distal embolization, target lesion reintervention (TLR), and ulcer healing rate. Major amputation-free survival and primary patency were calculated by Kaplan-Meier analysis.

Results:

A total of 71 patients were enrolled. Forty-eight (81.7%) patients presented critical limb ischemia (CLI) and 48.6% of them was calcification class 4 according to Peripheral Arterial Calcium Scoring System (PACSS). Chronic totally occluded (CTO) disease was the most common lesion in 66.0% of them and superficial femoral artery (SFA) was the most common segment in 59.6%. Technical success rate was 93.0%. One-year follow-up was finished in 25 (35.2%) patients. The primary patency and MAFS were 92.0%±27.6% and 96.0%±20.0% at 12 months, respectively. During the mean follow-up of 9.4±4.3 months, clinically-driven TLR occurred in 2 (2.8%) patients, and major and minor amputation occurred in 2 (2.8%) and 1 (1.4%) patient, respectively.

Conclusion:

The early results demonstrated that ELA was an effective treatment in de novo, in-stent restenosis (ISR) and CTO lesions. Meanwhile, ELA could prepare the lumen for the use of DCB and reduce the implantation of stents, especially in segments unsuitable for stenting. Mid-term and long-term results need to be awaited.

Keywords

arteriosclerotic obliterans excimer laser ablation critical limb ischemia drug-coated balloon thromboangiitis obliterans

Get full access to this article

View all access options for this article.

References

1.

Fowkes

FG

Rudan

D

Rudan

I

, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–1340.

2.

Adam

DJ

Bradbury

AW.

TASC II document on the management of peripheral arterial disease. Eur J Vasc Endovasc Surg. 2007;33(1):1–2.

3.

Hirsch

AT

Hartman

L

Town

RJ

, et al. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008;13(3):209–215.

4.

Schillinger

M

Sabeti

S

Loewe

C

, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–1888.

5.

Laird

JR

Katzen

BT

Scheinert

D

, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267–276.

6.

Schillinger

M

Sabeti

S

Dick

P

, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–2749.

7.

Laird

JR

Katzen

BT

Scheinert

D

, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19(1):1–9.

8.

Dippel

EJ

Makam

P

Kovach

R

, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 2015;8(1, pt A):92–101.

9.

Rocha-Singh

KJ

Zeller

T

Jaff

MR.

Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83(6):E212–E220.

10.

Idemoto

A

Okamoto

N

Tanaka

A

, et al. Impact of angioscopic evaluation for femoropopliteal in-stent restenosis before and after excimer laser atherectomy. Vasc Endovascular Surg. 2017;51(5):335–337.

11.

Fitzgerald

PJ

Ports

TA

Yock

PG.

Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound. Circulation. 1992;86(1):64–70.

12.

Topaz

O

Bernardo

NL

Shah

R

, et al. Effectiveness of excimer laser coronary angioplasty in acute myocardial infarction or in unstable angina pectoris. Am J Cardiol. 2001;87(7):849–855.

13.

Topaz

O

Minisi

AJ

Bernardo

NL

, et al. Alterations of platelet aggregation kinetics with ultraviolet laser emission: the “stunned platelet” phenomenon. Thromb Haemost. 2001;86(4):1087–1093.

14.

Gandini

R

Del Giudice

C

Merolla

S

, et al. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study. J Endovasc Ther. 2013;20(6):805–814.

15.

Adam

DJ

Beard

JD

Cleveland

T

, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925–1934.

16.

Bishu

K

Armstrong

EJ.

Supera self-expanding stents for endovascular treatment of femoropopliteal disease: a review of the clinical evidence. Vasc Health Risk Manag. 2015;11:387–395.

17.

Tellez

A

Dattilo

R

Mustapha

JA

, et al. Biological effect of orbital atherectomy and adjunctive paclitaxel-coated balloon therapy on vascular healing and drug retention: early experimental insights into the familial hypercholesterolaemic swine model of femoral artery stenosis. EuroIntervention. 2014;10(8):1002–1008.

18.

Odink

HF.

Long-term follow-up of laser-assisted angioplasty: analysis of factors influencing restenosis and patency. Vasc Surg. 1993;27:165–171.

19.

König

CW

Pusich

B

Tepe

G

, et al. Frequent embolization in peripheral angioplasty: detection with an embolism protection device (AngioGuard) and electron microscopy. Cardiovasc Intervent Radiol. 2003;26(4):334–339.

20.

Molloy

KJ

Nasim

A

London

NJ

, et al. Percutaneous transluminal angioplasty in the treatment of critical limb ischemia. J Endovasc Ther. 2003;10:298–303.

21.

Brown

KT

Moore

ED

Getrajdman

GI

, et al. Infrapopliteal angioplasty: long-term follow up. J Vasc Interv Radiol. 1993;4:139–144.

22.

Narula

N

Dannenberg

AJ

Olin

JW

, et al. Pathology of peripheral artery disease in patients with critical limb ischemia. J Am Coll Cardiol. 2018;72:2152–2163.

23.

Liistro

F

Porto

I

Angioli

P

, et al. Drugeluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATEBTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615–621.

24.

Schmidt

A

Ulrich

M

Winkler

B

, et al. Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease. Catheter Cardiovasc Interv. 2010;76:1047–1054.

25.

Steinkamp

HJ

Rademaker

J

Wissgott

C

, et al. Percutaneous transluminal laser angioplasty versus balloon dilation for treatment of popliteal artery occlusions. J Endovasc Ther. 2002;9(6):882–888.

26.

Liistro

F

Angioli

P

Ventoruzzo

G

, et al. Randomized controlled trial of Acotec Drug-Eluting Balloon versus plain balloon for below-the-knee angioplasty. JACC Cardiovasc Interv. 2020;13:2277–2286.

27.

Konijn

LCD

Wakkie

T

Spreen

MI

, et al. 10-Year paclitaxel dose-related outcomes of drug-eluting stents treated below the knee in patients with chronic limb-threatening ischemia (The PADI Trial). Cardiovasc Intervent Radiol. 2020;43(12):1881–1888.

28.

Singh

T

Kodenchery

M

Artham

S

, et al. Laser in infra-popliteal and popliteal stenosis (LIPS): retrospective review of laser-assisted balloon angioplasty versus balloon angioplasty alone for below knee peripheral arterial disease. Cardiovasc Interv Ther. 2014;29(2):109–116.

29.

Dong

Z

Pan

T

Fang

Y

, et al. Purified CD34+ cells versus peripheral blood mononuclear cells in the treatment of angiitis-induced no-option critical limb ischaemia: 12-month results of a prospective randomised single-blinded non-inferiority trial. EBioMedicine. 2018;35:46–57.

30.

Pan

T

Liu

H

Fang

Y

, et al. Predictors of responders to mononuclear stem cell-based therapeutic angiogenesis for no-option critical limb ischemia. Stem Cell Res Ther. 2019;10:15.

31.

Scheinert

D

Laird

J

Schroder

M

, et al. Excimer laser-assisted recanalization of long, chronic superficial femoral artery occlusions. J Endovasc Ther. 2001;8:156–166.